Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01809964 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
A Phase 2 study of Lateral Canthal Lines and Crows Feet, sponsored by Anterios.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 7
- Study locations
NCT01809964 is a Phase 2 study of Lateral Canthal Lines and Crows Feet that has completed, run by Anterios. The registered enrollment target is 109 participants, below the 332-participant average among 5 other Lateral Canthal Lines trials with a reported enrollment target (67% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT01809964, a Phase 2 study of Lateral Canthal Lines and Crows Feet, has completed, sponsored by Anterios.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to confirm the effect of ANT-1401 in the treatment of Lateral Canthal Lines.
Conditions Studied
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL ANT-1401
Study Locations (7)
Florida
- - Miami
- - Pinellas Park
- - West Palm Beach
Alabama
- - Birmingham
Kentucky
- - Louisville
Louisiana
- - Metairie
Tennessee
- - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01809964
The ClinicalTrials.gov registry entry for NCT01809964 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 5 other Lateral Canthal Lines trials with a reported enrollment target (67% lower). The listed sponsor is Anterios, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lateral Canthal Lines appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT01809964 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01809964 about?
NCT01809964 is a clinical study titled "Clinical Trial to Evaluate ANT-1401 in Crow's Feet". The purpose of this study is to confirm the effect of ANT-1401 in the treatment of Lateral Canthal Lines.
What is the current status of trial NCT01809964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2013-03. Estimated completion is 2013-10.
What conditions does trial NCT01809964 study?
This clinical trial studies the following conditions: Lateral Canthal Lines, Crows Feet.
What interventions are being tested in trial NCT01809964?
The interventions under investigation include: Vehicle (BIOLOGICAL), ANT-1401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01809964?
This trial is sponsored by Anterios, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01809964 being conducted?
This trial has 7 study locations across Alabama, Florida, Kentucky, Louisiana, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lateral Canthal Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
COMPLETED · Phase 2
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
COMPLETED · Phase 2
-
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
COMPLETED · Phase 2
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
COMPLETED · Phase 3
-
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.